8VC

8VC is the kind of firm that requires founders to read past the marketing copy. Joe Lonsdale’s Austin-based partnership, with over $6B in AUM, has built one of the more contrarian healthcare practices in venture by combining a multi-stage capital base with explicit, publicly published theses on healthcare and life sciences. The firm invests across seed through growth in digital health, health IT, biotech, life sciences tools, AI/ML in healthcare, and tech-enabled care delivery, with check sizes ranging from sub-Series A bets to $25M and up at growth. The firm’s published thesis pages on healthcare and life sciences are unusually substantive and are required reading for any founder considering an approach. The position 8VC stakes out is that healthcare is structurally broken in ways that vertical software and AI-native tools can address, and that the firm wants to back companies attacking those structural problems at scale.

The stated thesis on healthcare focuses on infrastructure and platform plays, particularly in supply chain, provider operations, payer technology, and care delivery models that decouple cost from labor intensity. The life sciences thesis emphasizes computational drug discovery, lab automation, and tools that compress the timeline from target to clinical candidate. AI/ML is treated as a horizontal capability across both verticals rather than as a separate sub-vertical. The implied target company profile spans early-stage software and platform companies that could plausibly become category-defining infrastructure layers, plus selective therapeutic and tools bets where computational approaches give a defensible edge. Founders building consumer wellness apps, single-product devices, or me-too SaaS in healthcare are unlikely to fit; founders building infrastructure that could plausibly serve hundreds of healthcare organizations or accelerate drug discovery at the platform level are the target.

The firm’s broader portfolio across all sectors is dominated by deep tech, defense, fintech, and infrastructure, which signals how 8VC thinks about healthcare: as another infrastructure-rich sector ripe for technical re-architecting rather than as a clinical services play. While specific healthcare portfolio names are not enumerated in the structured record, 8VC has been publicly associated with bets across health data, drug discovery, hospital operations software, and AI-driven biology platforms. Founders should review the firm’s portfolio page directly, paying attention to which sub-verticals have multiple investments versus single bets; concentration patterns are the cleanest signal of where the partnership has conviction.

With $6B+ in AUM and check sizes ranging up to $25M and beyond, 8VC has the capital base to lead at multiple stages. The firm regularly leads Series A and Series B in healthcare and participates meaningfully in growth rounds. Co-investment patterns tend to span deep-tech firms, healthcare specialists, and large multi-stage funds, with 8VC often taking the lead on technical and infrastructure diligence while specialists handle clinical and regulatory components. Founders should expect that 8VC’s check is sized for lead positioning and that the firm will want a board seat at most stages where it leads. The multi-stage capital base also means 8VC can follow into later rounds, which matters for capital-intensive infrastructure plays.

Decision-making at 8VC concentrates among the firm’s partners. While the structured record does not enumerate the healthcare-focused team members specifically, founders should research which partners have led recent healthcare and life sciences investments and target their outreach accordingly. Joe Lonsdale, the firm’s founding partner, is publicly active and influential on strategic direction but is unlikely to be the first point of contact for early-stage deals. Healthcare and life sciences deals typically run through partners and principals with domain focus.

Warm intros from existing portfolio founders, from operators inside Lonsdale’s broader network, and from co-investors at top deep-tech and healthcare firms carry the most weight. 8VC partners are unusually active publicly, with substantive writing on the firm’s website, frequent podcast appearances, and visible presence at industry conferences. Lonsdale himself is one of the more prolific public voices in venture, with a podcast and a stream of essays that telegraph the firm’s evolving worldview. Founders can use this public footprint to calibrate language and to identify which partner is currently most active in their sub-vertical. Cold inbound is plausible given the firm’s open thesis pages, but well-researched, partner-targeted outreach performs meaningfully better.

Approach 8VC when your company is building infrastructure, platform, or AI-native tools at a scale that could redefine a healthcare or life sciences sub-vertical. Do not approach for incremental SaaS, single-product devices, or consumer wellness brands. Among portfolio founders, the firm has a reputation for high conviction, fast decisions when interested, and a willingness to take contrarian positions that other firms will not. The flip side is a partnership with strong opinions; founders who want a quiet board partner may find 8VC’s level of strategic engagement intense. For founders building genuinely ambitious healthcare infrastructure, the combination of capital, conviction, and platform support is among the strongest available in the market.